Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase
ABSTRACTThis retrospective report presents the outcomes and adverse events (AEs) observed in 73 patients aged 60 years or older diagnosed with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (Ph-negative ALL) treated with a pediatric-inspired protocol incorporating either Pegylated (PE...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2329027 |
| _version_ | 1797246040324177920 |
|---|---|
| author | Maria Agustina Perusini Claire Andrews Eshetu G. Atenafu Vikas Gupta Dawn Maze Andre C. Schuh Karen WL. Yee Aniket Bankar Marta B. Davidson Guillaume Richard-Carpentier Steven M. Chan Jad Sibai Aaron D. Schimmer Mark D. Minden Hassan Sibai |
| author_facet | Maria Agustina Perusini Claire Andrews Eshetu G. Atenafu Vikas Gupta Dawn Maze Andre C. Schuh Karen WL. Yee Aniket Bankar Marta B. Davidson Guillaume Richard-Carpentier Steven M. Chan Jad Sibai Aaron D. Schimmer Mark D. Minden Hassan Sibai |
| author_sort | Maria Agustina Perusini |
| collection | DOAJ |
| description | ABSTRACTThis retrospective report presents the outcomes and adverse events (AEs) observed in 73 patients aged 60 years or older diagnosed with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (Ph-negative ALL) treated with a pediatric-inspired protocol incorporating either Pegylated (PEG-ASP) or Native Asparaginase (EC-ASP). Notably, 61% of patients experienced AEs of Grade III-IV severity. The most prevalent AEs included thrombosis (35.6%), febrile neutropenia (38.4%), and transaminitis (34.2%). AEs did not translate into significant differences concerning overall survival, leukemia-free survival, or early mortality. Furthermore, we observed a reduction in early mortality rates (11% vs. 20%) and an increase in median overall survival (54 vs. 48 months) compared to our previous data. These findings suggest that the utilization of a pediatric-inspired chemotherapy protocol, with ASP, is an effective and well-tolerated therapeutic option for older patients with Ph-negative ALL. However, it emphasizes the importance of diligent monitoring and close follow-up throughout treatment. |
| first_indexed | 2024-04-24T19:36:28Z |
| format | Article |
| id | doaj.art-860fe86b5d6c425b93b7c8cf45f165fa |
| institution | Directory Open Access Journal |
| issn | 1607-8454 |
| language | English |
| last_indexed | 2024-04-24T19:36:28Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj.art-860fe86b5d6c425b93b7c8cf45f165fa2024-03-25T13:54:45ZengTaylor & Francis GroupHematology1607-84542024-12-0129110.1080/16078454.2024.2329027Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native AsparaginaseMaria Agustina Perusini0Claire Andrews1Eshetu G. Atenafu2Vikas Gupta3Dawn Maze4Andre C. Schuh5Karen WL. Yee6Aniket Bankar7Marta B. Davidson8Guillaume Richard-Carpentier9Steven M. Chan10Jad Sibai11Aaron D. Schimmer12Mark D. Minden13Hassan Sibai14Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, CanadaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, CanadaDepartment of Biostatistics, Princess Margaret Cancer Centre, Toronto, CanadaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, CanadaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, CanadaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, CanadaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, CanadaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, CanadaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, CanadaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, CanadaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, CanadaUniversity Health Network, Toronto, CanadaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, CanadaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, CanadaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, CanadaABSTRACTThis retrospective report presents the outcomes and adverse events (AEs) observed in 73 patients aged 60 years or older diagnosed with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (Ph-negative ALL) treated with a pediatric-inspired protocol incorporating either Pegylated (PEG-ASP) or Native Asparaginase (EC-ASP). Notably, 61% of patients experienced AEs of Grade III-IV severity. The most prevalent AEs included thrombosis (35.6%), febrile neutropenia (38.4%), and transaminitis (34.2%). AEs did not translate into significant differences concerning overall survival, leukemia-free survival, or early mortality. Furthermore, we observed a reduction in early mortality rates (11% vs. 20%) and an increase in median overall survival (54 vs. 48 months) compared to our previous data. These findings suggest that the utilization of a pediatric-inspired chemotherapy protocol, with ASP, is an effective and well-tolerated therapeutic option for older patients with Ph-negative ALL. However, it emphasizes the importance of diligent monitoring and close follow-up throughout treatment.https://www.tandfonline.com/doi/10.1080/16078454.2024.2329027Acute lymphoblastic leukemia; ALLelderly patientschemotherapy |
| spellingShingle | Maria Agustina Perusini Claire Andrews Eshetu G. Atenafu Vikas Gupta Dawn Maze Andre C. Schuh Karen WL. Yee Aniket Bankar Marta B. Davidson Guillaume Richard-Carpentier Steven M. Chan Jad Sibai Aaron D. Schimmer Mark D. Minden Hassan Sibai Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase Hematology Acute lymphoblastic leukemia; ALL elderly patients chemotherapy |
| title | Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase |
| title_full | Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase |
| title_fullStr | Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase |
| title_full_unstemmed | Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase |
| title_short | Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase |
| title_sort | outcomes and adverse events in older acute lymphoblastic leukemia patients treated with a pediatric inspired protocol with pegylated or native asparaginase |
| topic | Acute lymphoblastic leukemia; ALL elderly patients chemotherapy |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2024.2329027 |
| work_keys_str_mv | AT mariaagustinaperusini outcomesandadverseeventsinolderacutelymphoblasticleukemiapatientstreatedwithapediatricinspiredprotocolwithpegylatedornativeasparaginase AT claireandrews outcomesandadverseeventsinolderacutelymphoblasticleukemiapatientstreatedwithapediatricinspiredprotocolwithpegylatedornativeasparaginase AT eshetugatenafu outcomesandadverseeventsinolderacutelymphoblasticleukemiapatientstreatedwithapediatricinspiredprotocolwithpegylatedornativeasparaginase AT vikasgupta outcomesandadverseeventsinolderacutelymphoblasticleukemiapatientstreatedwithapediatricinspiredprotocolwithpegylatedornativeasparaginase AT dawnmaze outcomesandadverseeventsinolderacutelymphoblasticleukemiapatientstreatedwithapediatricinspiredprotocolwithpegylatedornativeasparaginase AT andrecschuh outcomesandadverseeventsinolderacutelymphoblasticleukemiapatientstreatedwithapediatricinspiredprotocolwithpegylatedornativeasparaginase AT karenwlyee outcomesandadverseeventsinolderacutelymphoblasticleukemiapatientstreatedwithapediatricinspiredprotocolwithpegylatedornativeasparaginase AT aniketbankar outcomesandadverseeventsinolderacutelymphoblasticleukemiapatientstreatedwithapediatricinspiredprotocolwithpegylatedornativeasparaginase AT martabdavidson outcomesandadverseeventsinolderacutelymphoblasticleukemiapatientstreatedwithapediatricinspiredprotocolwithpegylatedornativeasparaginase AT guillaumerichardcarpentier outcomesandadverseeventsinolderacutelymphoblasticleukemiapatientstreatedwithapediatricinspiredprotocolwithpegylatedornativeasparaginase AT stevenmchan outcomesandadverseeventsinolderacutelymphoblasticleukemiapatientstreatedwithapediatricinspiredprotocolwithpegylatedornativeasparaginase AT jadsibai outcomesandadverseeventsinolderacutelymphoblasticleukemiapatientstreatedwithapediatricinspiredprotocolwithpegylatedornativeasparaginase AT aarondschimmer outcomesandadverseeventsinolderacutelymphoblasticleukemiapatientstreatedwithapediatricinspiredprotocolwithpegylatedornativeasparaginase AT markdminden outcomesandadverseeventsinolderacutelymphoblasticleukemiapatientstreatedwithapediatricinspiredprotocolwithpegylatedornativeasparaginase AT hassansibai outcomesandadverseeventsinolderacutelymphoblasticleukemiapatientstreatedwithapediatricinspiredprotocolwithpegylatedornativeasparaginase |